Market Cap 6.68B
Revenue (ttm) 3.44B
Net Income (ttm) -8.60M
EPS (ttm) N/A
PE Ratio 26.78
Forward PE 21.10
Profit Margin -0.25%
Debt to Equity Ratio 0.68
Volume 2,775,284
Avg Vol 2,183,142
Day's Range N/A - N/A
Shares Out 152.23M
Stochastic %K 89%
Beta 1.12
Analysts Strong Sell
Price Target $49.15

Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative...

Industry: Medical Devices
Sector: Healthcare
Phone: 978 663 3660
Fax: 978 663 5585
Address:
40 Manning Road, Billerica, United States
stockpicker63
stockpicker63 May. 6 at 6:58 PM
Watch $BRKR
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 10:37 AM
$BRKR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.02 down -81.82% YoY • Reported revenue of $823.4M up 2.75% YoY • Bruker reconfirms FY2026 guidance, expecting revenues of $3.57B, an increase of 4% to 5% year-over-year, with 1% to 2% organic growth. Non-GAAP EPS is projected to be $2.10 to $2.15, up 15% to 17% year-over-year.
0 · Reply
Ren_Stimpy
Ren_Stimpy May. 1 at 11:59 AM
$STIM $BRKR $BIO $AHCO $ENOV this is just a few examples of companies in the medical device industry that sold more of their shares than they currently have. Add up the percentage of institutional, insiders and shares shorted. All well over 💯 percent!! How will the short sellers buy back shares that don’t exist? I think short sellers are in trouble of losing big betting against this industry.
0 · Reply
CHItraders
CHItraders Apr. 17 at 1:15 PM
$BRKR Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 9 at 2:39 AM
$BRKR RSI: 71.21, MACD: -0.3937 Vol: 1.50, MA20: 35.16, MA50: 38.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 31 at 2:44 AM
$BRKR Share Price: $34.31 Contract Selected: Sep 18, 2026 $35 Calls Buy Zone: $4.17 – $5.15 Target Zone: $7.07 – $8.65 Potential Upside: 60% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
topstockalerts
topstockalerts Mar. 17 at 5:18 PM
Shares of Bruker Corporation and 10x Genomics fell after Satya Nadella highlighted GigaTIME, an AI model developed by Microsoft, Providence Health, and the University of Washington that can predict multiplex immunofluorescence results from H&E pathology slides. The selloff reflected concerns that AI could reduce demand for spatial proteomics, but Wolfe Research argued the reaction was overdone, noting these tools are not yet widely used in clinical settings and the underlying study was published months ago in Cell. GigaTIME uses multimodal AI trained on 40 million cells and tested across 14,000+ patients, analyzing 21 protein markers including PD-L1. However, Wolfe said this marker set is relatively limited compared to traditional methods, suggesting the technology remains early-stage rather than a near-term replacement. $BRKR $TXG
2 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 7:26 PM
$BRKR Current Stock Price: $38.94 Contracts to trade: $40.0 BRKR Mar 20 2026 Call Entry: $1.15 Exit: $2.09 ROI: 81% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JackDarwin
JackDarwin Feb. 24 at 11:50 AM
$BRKR Bullish Engulfing Candlestick Pattern
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 20 at 6:23 PM
$BRKR Share Price: $38.06 Contract Selected: Sep 18, 2026 $45 Calls Buy Zone: $3.15 – $3.89 Target Zone: $5.05 – $6.17 Potential Upside: 52% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on BRKR
Bruker price target raised to $45 from $40 at Stifel

2026-05-08T13:10:34.000Z - 7 days ago

Bruker price target raised to $45 from $40 at Stifel


Bruker price target raised to $45 from $43 at TD Cowen

2026-05-07T20:19:32.000Z - 8 days ago

Bruker price target raised to $45 from $43 at TD Cowen


Bruker price target raised to $45 from $40 at UBS

2026-05-07T14:17:50.000Z - 8 days ago

Bruker price target raised to $45 from $40 at UBS


Bruker price target raised to $53 from $45 at Barclays

2026-05-07T12:07:54.000Z - 8 days ago

Bruker price target raised to $53 from $45 at Barclays


Bruker price target raised to $44 from $40 at Citi

2026-05-07T10:51:26.000Z - 8 days ago

Bruker price target raised to $44 from $40 at Citi


Bruker reports Q1 adjusted EPS 31c, consensus 23c

2026-05-07T09:37:03.000Z - 8 days ago

Bruker reports Q1 adjusted EPS 31c, consensus 23c


Bruker Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 9 days ago

Bruker Earnings Call Transcript: Q1 2026


Bruker Reports First Quarter 2026 Financial Results

May 6, 2026, 6:30 AM EDT - 9 days ago

Bruker Reports First Quarter 2026 Financial Results


Bruker price target lowered to $45 from $50 at Barclays

2026-04-14T10:49:44.000Z - 4 weeks ago

Bruker price target lowered to $45 from $50 at Barclays


Bruker unveils NMR products, workflow solutions at ENC 2026

2026-04-13T11:11:40.000Z - 4 weeks ago

Bruker unveils NMR products, workflow solutions at ENC 2026


Bruker appoints Bernard to its Board of Directors

2026-04-01T11:41:48.000Z - 6 weeks ago

Bruker appoints Bernard to its Board of Directors

QGEN


Bruker price target lowered to $50 from $58 at Guggenheim

2026-03-30T11:56:01.000Z - 6 weeks ago

Bruker price target lowered to $50 from $58 at Guggenheim


Bruker price target lowered to $49 from $60 at BofA

2026-02-13T16:10:30.000Z - 3 months ago

Bruker price target lowered to $49 from $60 at BofA


Bruker price target lowered to $35 from $40 at Goldman Sachs

2026-02-13T14:45:16.000Z - 3 months ago

Bruker price target lowered to $35 from $40 at Goldman Sachs


Bruker price target raised to $49 from $43 at UBS

2026-02-13T14:35:44.000Z - 3 months ago

Bruker price target raised to $49 from $43 at UBS


Bruker price target lowered to $43 from $53 at TD Cowen

2026-02-13T13:45:41.000Z - 3 months ago

Bruker price target lowered to $43 from $53 at TD Cowen


Bruker Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:30 AM EST - 3 months ago

Bruker Earnings Call Transcript: Q4 2025


Bruker Announces Quarterly Preferred Stock Dividend

Feb 5, 2026, 4:05 PM EST - 3 months ago

Bruker Announces Quarterly Preferred Stock Dividend


Bruker Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 4 months ago

Bruker Transcript: 44th Annual J.P. Morgan Healthcare Conference


Bruker Transcript: 53rd Annual Nasdaq Investor Conference

Dec 10, 2025, 5:00 AM EST - 5 months ago

Bruker Transcript: 53rd Annual Nasdaq Investor Conference


Indaba Capital Announces Sale of AST Revolution to Bruker

Nov 24, 2025, 9:00 AM EST - 6 months ago

Indaba Capital Announces Sale of AST Revolution to Bruker


Bruker Transcript: Wolfe Research Healthcare Conference 2025

Nov 17, 2025, 4:00 PM EST - 6 months ago

Bruker Transcript: Wolfe Research Healthcare Conference 2025


Bruker Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 6 months ago

Bruker Earnings Call Transcript: Q3 2025


Bruker Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 7:00 AM EST - 6 months ago

Bruker Reports Third Quarter 2025 Financial Results


Bruker Announces Quarterly Dividend

Aug 12, 2025, 7:00 AM EDT - 9 months ago

Bruker Announces Quarterly Dividend


Bruker Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 10 months ago

Bruker Earnings Call Transcript: Q2 2025


Bruker Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 7:00 AM EDT - 10 months ago

Bruker Reports Second Quarter 2025 Financial Results


Bruker Launches Revolutionary timsOmniTM Mass Spectrometer

May 30, 2025, 8:00 AM EDT - 1 year ago

Bruker Launches Revolutionary timsOmniTM Mass Spectrometer


Bruker Transcript: AGM 2025

May 29, 2025, 10:00 AM EDT - 1 year ago

Bruker Transcript: AGM 2025


Bruker Earnings Call Transcript: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

Bruker Earnings Call Transcript: Q1 2025


Bruker Reports First Quarter 2025 Financial Results

May 7, 2025, 7:00 AM EDT - 1 year ago

Bruker Reports First Quarter 2025 Financial Results


Bruker Introduces nVista 2P Miniature Microscope

Apr 17, 2025, 9:00 AM EDT - 1 year ago

Bruker Introduces nVista 2P Miniature Microscope


stockpicker63
stockpicker63 May. 6 at 6:58 PM
Watch $BRKR
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 10:37 AM
$BRKR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.02 down -81.82% YoY • Reported revenue of $823.4M up 2.75% YoY • Bruker reconfirms FY2026 guidance, expecting revenues of $3.57B, an increase of 4% to 5% year-over-year, with 1% to 2% organic growth. Non-GAAP EPS is projected to be $2.10 to $2.15, up 15% to 17% year-over-year.
0 · Reply
Ren_Stimpy
Ren_Stimpy May. 1 at 11:59 AM
$STIM $BRKR $BIO $AHCO $ENOV this is just a few examples of companies in the medical device industry that sold more of their shares than they currently have. Add up the percentage of institutional, insiders and shares shorted. All well over 💯 percent!! How will the short sellers buy back shares that don’t exist? I think short sellers are in trouble of losing big betting against this industry.
0 · Reply
CHItraders
CHItraders Apr. 17 at 1:15 PM
$BRKR Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 9 at 2:39 AM
$BRKR RSI: 71.21, MACD: -0.3937 Vol: 1.50, MA20: 35.16, MA50: 38.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 31 at 2:44 AM
$BRKR Share Price: $34.31 Contract Selected: Sep 18, 2026 $35 Calls Buy Zone: $4.17 – $5.15 Target Zone: $7.07 – $8.65 Potential Upside: 60% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
topstockalerts
topstockalerts Mar. 17 at 5:18 PM
Shares of Bruker Corporation and 10x Genomics fell after Satya Nadella highlighted GigaTIME, an AI model developed by Microsoft, Providence Health, and the University of Washington that can predict multiplex immunofluorescence results from H&E pathology slides. The selloff reflected concerns that AI could reduce demand for spatial proteomics, but Wolfe Research argued the reaction was overdone, noting these tools are not yet widely used in clinical settings and the underlying study was published months ago in Cell. GigaTIME uses multimodal AI trained on 40 million cells and tested across 14,000+ patients, analyzing 21 protein markers including PD-L1. However, Wolfe said this marker set is relatively limited compared to traditional methods, suggesting the technology remains early-stage rather than a near-term replacement. $BRKR $TXG
2 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 7:26 PM
$BRKR Current Stock Price: $38.94 Contracts to trade: $40.0 BRKR Mar 20 2026 Call Entry: $1.15 Exit: $2.09 ROI: 81% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JackDarwin
JackDarwin Feb. 24 at 11:50 AM
$BRKR Bullish Engulfing Candlestick Pattern
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 20 at 6:23 PM
$BRKR Share Price: $38.06 Contract Selected: Sep 18, 2026 $45 Calls Buy Zone: $3.15 – $3.89 Target Zone: $5.05 – $6.17 Potential Upside: 52% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MaryThomas194
MaryThomas194 Feb. 18 at 12:42 PM
$BRKR Life sciences tools leader benefiting from research spend normalization.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 16 at 1:52 PM
$BRKR RSI: 12.41, MACD: -2.5767 Vol: 4.45, MA20: 44.79, MA50: 46.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
alshamiak
alshamiak Feb. 12 at 6:30 PM
$BRKR #swing edit: 33.32 https://usastockhunteracademy.com/en/swing-indicator-vip/
0 · Reply
sweetpotatocow
sweetpotatocow Feb. 12 at 2:28 PM
$BRKR picked the wrong horse to bet on for ER pop. 😞
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 12 at 12:08 PM
$BRKR Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.10 up 11.11% YoY • Reported revenue of $977.2M down -0.24% YoY • Bruker expects FY26 revenues of $3.57B, an increase of 4% to 5% year-over-year, with non-GAAP EPS projected at $2.10 to $2.15, up 15% to 17% year-over-year.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 10 at 7:53 PM
$BRKR Share Price: $41.98 Contract Selected: Sep 18, 2026 $45 Calls Buy Zone: $4.93 – $6.09 Target Zone: $9.26 – $11.32 Potential Upside: 77% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Estimize
Estimize Feb. 10 at 1:58 PM
Wall St is expecting 0.65 EPS for $BRKR Q4 [Reporting 02/12 BMO] http://www.estimize.com/intro/brkr?chart=historical&metric_name=eps&utm_co
0 · Reply
sweetpotatocow
sweetpotatocow Feb. 5 at 7:57 PM
$BRKR is this affected due to public health spending cuts?
1 · Reply
MoneyMcDuck
MoneyMcDuck Feb. 5 at 6:56 PM
$BRKR keeping an eye on this one in the coming days. Looking for a reversal here for a potential trade opportunity.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 12:28 PM
$BRKR RSI: 24.97, MACD: -1.1022 Vol: 3.52, MA20: 49.29, MA50: 48.03 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply